Sulindac sulfone

SKU: orb1305638

Description

Sulindac sulfone, a metabolite of the anti-inflammatory drug sulindac, acts as an aldose reductase inhibitor with an IC50 of 367 nM. This compound is utilized in research on diabetic complications, serving as a tool for in vitro enzymatic studies and in vivo metabolic investigations.

Research Area

Cell Biology

Key Properties

• CAS Number: 59864-04-9
• MW: 372.41
• Purity: >98%
• Formula: C₂₀H₁₇FO₄S
• SMILES: CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C\c1ccc(cc1)S(C)(=O)=O
• Target: PDE (Phosphodiesterase)
• Solubility: Soluble in DMSO (up to 25 mg/ml).

Bioactivity

• Target IC50:
  Aldose reductase:367 nM
• In Vivo:
  In vivo: Sulindac sulfone is capable of reducing the incidence, multiplicity, and tumor burden in the azoxymethane AOM rat model of colorectal cancer. Sulindac sulfone had no effect on the growth of HCA-7, HCT-116 xenografts, and cancer cell xenografts .
• In Vitro:
  In vitro: Sulindac sulfone treatment also inhibited PGE2 production by HCA-7 cells with an IC50 of 360 mmol/L. Sulindac sulfone at 100 mmol/L reduced 6-ketoPGFα by 29.2%. Sulindac sulfone reduced the colony number of HCA-7 and HCT-116 with an EC50 of 50 mmol/l. Sulindac sulfone significantly decreased the expression of total cellular β-catenin (50% of control), pro-caspase 3 (49%), cyclin D1 (51%), and PPARδ (65%) in SW480 cells. No significant alteration in pro-caspase 3 or β-catenin expression was found in HCA7, LS174, or Caco-2 cells treated with sulindac sulfone. A dose-dependent reduction in TCF-mediated transcriptional activity was also observed in SW480 cells .

Storage & Handling

• Storage: RT
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Sulindac sulfone, Exisulind, Inhibitor, inhibit, Aldose Reductase, COX-2

Compound Identifiers

PubChem CID

6158261